Research Report Identifies Chimerix, Evolent Health, ABIOMED, Syndax Pharmaceuticals, Independence Realty Trust, and Selecta Biosciences with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chimerix, Inc. (NASDAQ:CMRX), Evolent Health, Inc (NYSE:EVH), ABIOMED, Inc. (NASDAQ:ABMD), Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), Independence Realty Trust, Inc. (NYSE:IRT), and Selecta Biosciences, Inc. (NASDAQ:SELB), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CMRX DOWNLOAD: http://MarketSourceResearch.com/register/?so=CMRX
EVH DOWNLOAD: http://MarketSourceResearch.com/register/?so=EVH
ABMD DOWNLOAD: http://MarketSourceResearch.com/register/?so=ABMD
SNDX DOWNLOAD: http://MarketSourceResearch.com/register/?so=SNDX
IRT DOWNLOAD: http://MarketSourceResearch.com/register/?so=IRT
SELB DOWNLOAD: http://MarketSourceResearch.com/register/?so=SELB

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Chimerix, Inc. (NASDAQ:CMRX), Evolent Health, Inc (NYSE:EVH), ABIOMED, Inc. (NASDAQ:ABMD), Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), Independence Realty Trust, Inc. (NYSE:IRT), and Selecta Biosciences, Inc. (NASDAQ:SELB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CHIMERIX, INC. (CMRX) REPORT OVERVIEW

Chimerix's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Chimerix reported revenue of $4.86MM vs $1.84MM (up 163.77%) and analysts estimated basic earnings per share -$0.29 vs -$0.40. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Chimerix reported revenue of $7.22MM vs $4.49MM (up 60.57%) and analysts estimated basic earnings per share -$1.43 vs -$1.51. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$1.23 and is expected to report on March 3rd, 2020.

To read the full Chimerix, Inc. (CMRX) report, download it here: http://MarketSourceResearch.com/register/?so=CMRX

-----------------------------------------

EVOLENT HEALTH, INC (EVH) REPORT OVERVIEW

Evolent Health's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Evolent Health reported revenue of $193.10MM vs $113.73MM (up 69.79%) and analysts estimated basic earnings per share -$0.21 vs -$0.14. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Evolent Health reported revenue of $627.06MM vs $434.95MM (up 44.17%) and analysts estimated basic earnings per share -$0.68 vs -$0.94. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.03. The estimated EPS forecast for the next fiscal year is -$0.23 and is expected to report on February 25th, 2020.

To read the full Evolent Health, Inc (EVH) report, download it here: http://MarketSourceResearch.com/register/?so=EVH

-----------------------------------------

ABIOMED, INC. (ABMD) REPORT OVERVIEW

ABIOMED's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, ABIOMED reported revenue of $200.56MM vs $154.02MM (up 30.22%) and analysts estimated basic earnings per share $1.00 vs $0.30 (up 233.33%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, ABIOMED reported revenue of $593.75MM vs $445.30MM (up 33.34%) and analysts estimated basic earnings per share $2.54 vs $1.21 (up 109.92%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.80. The estimated EPS forecast for the next fiscal year is $4.94 and is expected to report on May 2nd, 2019.

To read the full ABIOMED, Inc. (ABMD) report, download it here: http://MarketSourceResearch.com/register/?so=ABMD

-----------------------------------------

SYNDAX PHARMACEUTICALS, INC. (SNDX) REPORT OVERVIEW

Syndax Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Syndax Pharmaceuticals reported revenue of $0.38MM vs $1.19MM (down 68.15%) and basic earnings per share -$0.71 vs -$0.81. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Syndax Pharmaceuticals reported revenue of $1.52MM vs $2.11MM (down 28.04%) and analysts estimated basic earnings per share -$2.92 vs -$2.90. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.79. The estimated EPS forecast for the next fiscal year is -$2.09 and is expected to report on March 5th, 2020.

To read the full Syndax Pharmaceuticals, Inc. (SNDX) report, download it here: http://MarketSourceResearch.com/register/?so=SNDX

-----------------------------------------

INDEPENDENCE REALTY TRUST, INC. (IRT) REPORT OVERVIEW

Independence Realty Trust's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Independence Realty Trust reported revenue of $49.81MM vs $42.45MM (up 17.34%) and analysts estimated basic earnings per share $0.17 vs $0.06 (up 183.33%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Independence Realty Trust reported revenue of $191.23MM vs $161.22MM (up 18.62%) and analysts estimated basic earnings per share $0.30 vs $0.41 (down 26.83%). Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.18. The estimated EPS forecast for the next fiscal year is $0.81 and is expected to report on February 20th, 2020.

To read the full Independence Realty Trust, Inc. (IRT) report, download it here: http://MarketSourceResearch.com/register/?so=IRT

-----------------------------------------

SELECTA BIOSCIENCES, INC. (SELB) REPORT OVERVIEW

Selecta Biosciences' Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Selecta Biosciences reported revenue of $0.90MM vs $0.21MM (up 336.23%) and analysts estimated basic earnings per share -$2.92 vs -$3.20. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.71. The estimated EPS forecast for the next fiscal year is -$1.24 and is expected to report on March 20th, 2020.

To read the full Selecta Biosciences, Inc. (SELB) report, download it here: http://MarketSourceResearch.com/register/?so=SELB

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Jim Patterson, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.